Clinical factor-based risk stratification for precision therapy in locally advanced squamous cell carcinoma of the uterine cervix.
Feng-Yuan LiuWei-Chun ChenYu-Bin PanChun-Chieh WangYun-Hsin TangHung-Hsueh ChouAngel ChaoLan-Yan YangChyong-Huey LaiPublished in: Cancer medicine (2024)
Age, primary tumor MTV, and positive PALN on PET/CT may serve as independent predictors of poor survival in patients with locally advanced cervical SCC. Our findings indicate that patients without any adverse factors can receive standard CCRT, whereas those with at least one adverse factor can consider novel combination therapies or clinical trials.
Keyphrases
- locally advanced
- squamous cell carcinoma
- pet ct
- rectal cancer
- neoadjuvant chemotherapy
- clinical trial
- end stage renal disease
- radiation therapy
- phase ii study
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- stem cells
- adverse drug
- randomized controlled trial
- mesenchymal stem cells
- open label
- electronic health record
- double blind
- smoking cessation